To investigate the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) combined with levosimendan in patients with severe acute heart failure.

The clinical data of 120 patients with severe acute heart failure admitted to our hospital from April 2023 to December 2024 were retrospectively analyzed. There were 80 males and 40 females, the age ranged from 53 to 75 years, with an average of (66.32±6.03) years. They were divided into observation group and control group by the different treatment methods, with 60 cases in each group. The control group was treated with rhBNP on the basis of conventional treatment, and the observation group was combined with levosimendan; Both of them were treated for 2 weeks. The left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), N-terminal brain natriuretic peptide precursor (NT-proBNP), myocardial troponin I (cTnI), myocardial creatine kinase isoenzyme MB (CK-MB), and soluble suppression of tumorigenicity 2 (sST2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Minnesota heart failure quality of life (MLHFQ) score, 6-minute walking test (6MWT) at before and after treatment 2 weeks and adverse reactions were compared between the two groups.

After treatment for 2 weeks, the LVEF in observation group was significantly higher than that in control group, LVEDD and LVESE were significantly lower (P<0.05); after treatment for 2 weeks, the levels of NT-proBNP, cTnI, CK-MB, sST2, TNF-α, IL-6 and MLHFQ in observation group were significantly lower than those of the control group, and the 6MWT was significantly longer (P<0.05). But there was no statistical significance in the total incidence of adverse reactions between the two groups (P>0.05).

rhBNP combined with leveo-simendan can promote the recovery of cardiac function and improve the quality of life in patients with severe acute heart failure, which is safe and controllable, and has clinical promotion value.